TY - JOUR
T1 - FSHD2- and BAMS-associated mutations confer opposing effects on SMCHD1 function
AU - Gurzau, Alexandra D.
AU - Chen, Kelan
AU - Xue, Shifeng
AU - Dai, Weiwen
AU - Lucet, Isabelle S.
AU - Ly, Thanh Thao Nguyen
AU - Reversade, Bruno
AU - Blewitt, Marnie E.
AU - Murphy, James M.
N1 - Generated from Scopus record by KAUST IRTS on 2023-02-15
PY - 2018/6/22
Y1 - 2018/6/22
N2 - Structural maintenance of chromosomes flexible hinge domain-containing 1 (Smchd1) plays important roles in epigenetic silencing and normal mammalian development. Recently, heterozygous mutations in SMCHD1 have been reported in two disparate disorders: facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS). FSHD2-associated mutations lead to loss of function; however, whether BAMS is associated with loss- or gain-of-function mutations in SMCHD1 is unclear. Here, we have assessed the effect of SMCHD1 missense mutations from FSHD2 and BAMS patients on ATP hydrolysis activity and protein conformation and the effect of BAMS mutations on craniofacial development in a Xenopus model. These data demonstrated that FSHD2 mutations only result in decreased ATP hydrolysis, whereas many BAMS mutations can result in elevated ATPase activity and decreased eye size in Xenopus. Interestingly, a mutation reported in both an FSHD2 patient and a BAMS patient results in increased ATPase activity and a smaller Xenopus eye size. Mutations in the extended ATPase domain increased catalytic activity, suggesting critical regulatory intramolecular interactions and the possibility of targeting this region therapeutically to boost SMCHD1’s activity to counter FSHD.
AB - Structural maintenance of chromosomes flexible hinge domain-containing 1 (Smchd1) plays important roles in epigenetic silencing and normal mammalian development. Recently, heterozygous mutations in SMCHD1 have been reported in two disparate disorders: facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS). FSHD2-associated mutations lead to loss of function; however, whether BAMS is associated with loss- or gain-of-function mutations in SMCHD1 is unclear. Here, we have assessed the effect of SMCHD1 missense mutations from FSHD2 and BAMS patients on ATP hydrolysis activity and protein conformation and the effect of BAMS mutations on craniofacial development in a Xenopus model. These data demonstrated that FSHD2 mutations only result in decreased ATP hydrolysis, whereas many BAMS mutations can result in elevated ATPase activity and decreased eye size in Xenopus. Interestingly, a mutation reported in both an FSHD2 patient and a BAMS patient results in increased ATPase activity and a smaller Xenopus eye size. Mutations in the extended ATPase domain increased catalytic activity, suggesting critical regulatory intramolecular interactions and the possibility of targeting this region therapeutically to boost SMCHD1’s activity to counter FSHD.
UR - https://linkinghub.elsevier.com/retrieve/pii/S0021925820399671
UR - http://www.scopus.com/inward/record.url?scp=85048977553&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA118.003104
DO - 10.1074/jbc.RA118.003104
M3 - Article
SN - 1083-351X
VL - 293
SP - 9841
EP - 9853
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 25
ER -